Study aim: The effect of curcumin supplementation on clinical symptoms, acute phase reactants and cytokine interleukin 6 in patients with new Covid-19 admitted to hospital Design: A double-blind clinical trial study with placebo Settings and conduct: This study is a double-blind randomized clinical trial that will be performed in Ali Asghar, Shahid Faghihi and Namazi hospitals in Shiraz. In this study, 76 eligible patients whose PCR test was positive and hospitalized will be divided into two groups of 38 using a random number table.Curcumin and placebo are made by Elixir Nano Drug Company. Participants/Inclusion and exclusion criteria: 1. They have a positive PCR test or lung involvement in the imaging 2- Inpatients who are non -intubated 3- They are obove18 years old 4- They have filled in the informed consent form. 5. They are not pregnant or breastfeeding. They do not have gallbladder inflammation or active gastrointestinal ulcers. 7. Patients do not have hemophilia or coagulation disease. Severe renal failure, ie GFR 30 ml / min or dialysis patients. 9- Signing informed written consent. 10. Not participating in other clinical trials at the same time. Exclusion criteria: Patients who are allergic to turmeric or curcumin supplement. Severe renal disease GFR 30 ml / min or dialysis patients. Patients who do not take more than a quarter of curcumin supplements during the study period. 4- Connecting the patient to the ventilator Intervention groups: The patients in the control group will receive the national standard diet for the treatment of coronavirus with placebo. Patients in the curcumin group are treated with 160 mg of nanocurcumin for 14 days in addition to the standard regimen during hospitalization. Main outcome variables: Clinical signs, Albumin concentration, CRP, ESR, Ferritin, Nutritional Risk Index (NRI), Interleukin-6